Mark Stone, the FSHD Society’s president and CEO, reported on the Society’s activities at his second quarter report to stakeholders on May 20, 2020. The webinar recording is now available… Read More »
CEO’s 2020 second quarter report
Dyne ramps up its FSHD program
Dyne Therapeutics, a Waltham, Massachusetts, biopharmaceutical company, announced yesterday that it is accelerating its FSHD therapy development program. Here is their press release: Dyne to evaluate therapies targeting genetic cause… Read More »
Fulcrum update on ReDUX4 trial
Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results May 13, 2020 at 7:00 AM EDT CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC),… Read More »
Participate in COVID-19 Survey
The FSHD Society is partnering with researchers on an important study of the impact of COVID-19 on the muscular dystrophy community. Please read this letter from Dr. Rabi Tawil and… Read More »
FSHD Society participating in #GivingTuesdayNow
This May 5, the FSHD Society is participating in #GivingTuesdayNow. This is a global day of giving and unity that arose as an emergency response to the unprecedented need caused… Read More »